1 Tate, J. E., Burton, A. H., Boschi-Pinto, C. & Parashar, U. D. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. Clin Infect Dis62 Suppl 2, S96-s105, doi:10.1093/cid/civ1013 (2016).
2 Lee, B. Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines. Hum Vaccin Immunother, 1-16, doi:10.1080/21645515.2020.1844525 (2020).
3 Holmgren, J., Parashar, U. D., Plotkin, S., Louis, J., Ng, S. P., Desauziers, E. et al. Correlates of protection for enteric vaccines. Vaccine35, 3355-3363, doi:10.1016/j.vaccine.2017.05.005 (2017).
4 Roestenberg, M., Hoogerwerf, M. A., Ferreira, D. M., Mordmüller, B. & Yazdanbakhsh, M. Experimental infection of human volunteers. Lancet Infect Dis18, e312-e322, doi:10.1016/s1473-3099(18)30177-4 (2018).
5 Brickley, E. B., Connor, R. I., Wieland-Alter, W. F., Collett, M. S., Hartford, M., Van Der Avoort, H. et al. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health4, e001613, doi:10.1136/bmjgh-2019-001613 (2019).
6 Brickley, E. B., Strauch, C. B., Wieland-Alter, W. F., Connor, R. I., Lin, S., Weiner, J. A. et al. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis217, 371-380, doi:10.1093/infdis/jix556 (2018).
7 Brickley, E. B., Wieland-Alter, W., Connor, R. I., Ackerman, M. E., Boesch, A. W., Arita, M. et al. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants. Clin Infect Dis67, S42-s50, doi:10.1093/cid/ciy603 (2018).
8 Hird, T. R. & Grassly, N. C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog8, e1002599, doi:10.1371/journal.ppat.1002599 (2012).
9 Wright, P. F., Wieland-Alter, W., Ilyushina, N. A., Hoen, A. G., Arita, M., Boesch, A. W. et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis209, 1628-1634, doi:10.1093/infdis/jit671 (2014).
10 Kirkpatrick, B. D., Colgate, E. R., Mychaleckyj, J. C., Haque, R., Dickson, D. M., Carmolli, M. P. et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg92, 744-751, doi:10.4269/ajtmh.14-0518 (2015).
11 Dennehy, P. H., Brady, R. C., Halperin, S. A., Ward, R. L., Alvey, J. C., Fischer, F. H., Jr. et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J24, 481-488 (2005).
12 Salinas, B., Perez Schael, I., Linhares, A. C., Ruiz Palacios, G. M., Guerrero, M. L., Yarzabal, J. P. et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J24, 807-816 (2005).
13 Vesikari, T., Karvonen, A., Korhonen, T., Espo, M., Lebacq, E., Forster, J. et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine22, 2836-2842, doi:10.1016/j.vaccine.2004.01.044 (2004).
14 Colgate, E. R., Haque, R., Dickson, D. M., Carmolli, M. P., Mychaleckyj, J. C., Nayak, U. et al. Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: A Randomized Controlled Trial. Clin Infect Dis63, 634-641, doi:10.1093/cid/ciw346 (2016).
15 Lee, B., Dickson, D. M., Alam, M., Afreen, S., Kader, A., Afrin, F. et al. The effect of increased inoculum on oral rotavirus vaccine take among infants in Dhaka, Bangladesh: A double-blind, parallel group, randomized, controlled trial. Vaccine38, 90-99, doi:10.1016/j.vaccine.2019.09.088 (2020).
16 Clarke, E. & Desselberger, U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol8, 1-17, doi:10.1038/mi.2014.114 (2015).
17 Lopman, B. A. & Pitzer, V. E. Waxing Understanding of Waning Immunity. J Infect Dis217, 851-853, doi:10.1093/infdis/jix670 (2018).
18 Angel, J., Steele, A. D. & Franco, M. A. Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother10, 3659-3671, doi:10.4161/hv.34361 (2014).
19 Fix, A., Kirkwood, C. D., Steele, D. & Flores, J. Next-generation rotavirus vaccine developers meeting: Summary of a meeting sponsored by PATH and the bill & melinda gates foundation (19-20 June 2019, Geneva). Vaccine38, 8247-8254, doi:10.1016/j.vaccine.2020.11.034 (2020).
20 Lee, B., Carmolli, M., Dickson, D. M., Colgate, E. R., Diehl, S. A., Uddin, M. I. et al. Rotavirus-Specific Immunoglobulin A Responses Are Impaired and Serve as a Suboptimal Correlate of Protection Among Infants in Bangladesh. Clin Infect Dis67, 186-192, doi:10.1093/cid/ciy076 (2018).
21 Crawford, S. E., Ramani, S., Tate, J. E., Parashar, U. D., Svensson, L., Hagbom, M. et al. Rotavirus infection. Nat Rev Dis Primers3, 17083, doi:10.1038/nrdp.2017.83 (2017).
22 Groome, M. J., Fairlie, L., Morrison, J., Fix, A., Koen, A., Masenya, M. et al. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis, doi:10.1016/s1473-3099(20)30001-3 (2020).
23 Groome, M. J., Koen, A., Fix, A., Page, N., Jose, L., Madhi, S. A. et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis, doi:10.1016/s1473-3099(17)30242-6 (2017).
24 Becker-Dreps, S., Vilchez, S., Velasquez, D., Moon, S. S., Hudgens, M. G., Zambrana, L. E. et al. Rotavirus-specific IgG antibodies from mothers' serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. Pediatr Infect Dis J34, 115-116, doi:10.1097/inf.0000000000000481 (2015).
25 Moon, S. S., Groome, M. J., Velasquez, D. E., Parashar, U. D., Jones, S., Koen, A. et al. Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants. Clin Infect Dis62, 157-165, doi:10.1093/cid/civ828 (2016).
26 Lee, B., Kader, A., Diehl, S. A., Colgate, E. R., Carmolli, M., Uddin, M. I. et al. Post-vaccination oral rotavirus vaccine shedding is not associated with vaccine immunogenicity or efficacy among infants in Bangladesh in The Ninth International Conference on Vaccines for Enteric Diseases. Albufeira, Portugal. 10 Oct 2017.
27 Naylor, C., Lu, M., Haque, R., Mondal, D., Buonomo, E., Nayak, U. et al. Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh. EBioMedicine2, 1759-1766, doi:10.1016/j.ebiom.2015.09.036 (2015).
28 Lee, B., Dickson, D. M., deCamp, A. C., Ross Colgate, E., Diehl, S. A., Uddin, M. I. et al. Histo-Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy. J Infect Dis217, 1399-1407, doi:10.1093/infdis/jiy054 (2018).
29 Liu, J., Gratz, J., Amour, C., Nshama, R., Walongo, T., Maro, A. et al. Optimization of Quantitative PCR Methods for Enteropathogen Detection. PLoS One11, e0158199, doi:10.1371/journal.pone.0158199 (2016).
30 Liu, J., Kibiki, G., Maro, V., Maro, A., Kumburu, H., Swai, N. et al. Multiplex reverse transcription PCR Luminex assay for detection and quantitation of viral agents of gastroenteritis. J Clin Virol50, 308-313, doi:10.1016/j.jcv.2010.12.009 (2011).